Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal Stromal Cell Therapy For The Treatment Of Acute Respiratory Distress Syndrome
NCT04447833Phase 1Completed
- Sponsor
- Uppsala University
- Start
- Jun 2020
- Primary completion
- Jan 2021
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KI-MSC-PL-205 in acute respiratory distress syndrome (ARDS) and coronavirus disease 2019 (COVID-19), sponsored by Uppsala University. Primary endpoint: Treatment Related Adverse Events of Interest at day 10. Started Jun 2020; status: completed.
02
Drugs
KI-MSC-PL-205
03
Conditions
acute respiratory distress syndrome (ARDS)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04447833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04447833.